Not Yet RecruitingNot Applicable

sCD163 in HELLP Syndrome

70 participantsStarted 2025-12-01

Plain-language summary

Primary Aim: \_To investigate the diagnostic potential of soluble CD163 (sCD163)as a novel biomarker for the early detection of HELLP syndrome, assessing its sensitivity and specificity compared to current diagnostic markers. Secondary Aims: 1. To evaluate the correlation between sCD163 levels and the clinical severity of HELLP syndrome, including complications such as liver dysfunction, thrombocytopenia, and hemolysis. 2. To compare sCD163 levels across different stages of HELLP syndrome (partial vs. complete and other hypertensive disorders of pregnancy (e.g., preeclampsia).

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pregnant women meeting complete HELLP criteria:
✓. Gestational age (20-42) weeks
✓. Normotensive pregnant women (BP \<140/90 mmHg, no proteinuria).
✓. Gestational age-matched

Exclusion criteria

✕. Chronic medical conditionsaffecting sCD163 levels:
✕. Fetal anomalies or intrauterine fetal demise at diagnosis.
✕. Use of immunosuppressive therapies (e.g., corticosteroids beyond standard HELLP management).
✕. Incomplete clinical/laboratory data for HELLP classification.
✕. Other gestational disease such as gestational DM

What they're measuring

Comparison of sCD163 level in the 2 study groups

Timeframe: baseline

Trial details

NCT IDNCT07209748

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

Contact for this trial

Asmaa Ragab Hamed, Master

01022866965 asmaaaaaaaa99@gmail.com

View on ClinicalTrials.gov More HELLP Syndrome Complicating Pregnancy trials